| Positive Rankings |
Estimated Revenue Growth
Cara Therapeutics Inc. rank is 25 |
90 Day Gain
Cara Therapeutics Inc. rank is 136 |
Low vPut/Call
Cara Therapeutics Inc. has a low Put/Call ratio of 0.07 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Cara Therapeutics Inc. is ranked 184. |
Debt-to-Equity
Cara Therapeutics Inc. rank is 224 |
10 Day Gain
Cara Therapeutics Inc. rank is 272 |
Low Put/Call
Cara Therapeutics Inc. has a low Put/Call ratio of 0.11 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Cara Therapeutics Inc. is ranked 280. |
Highest Cash Growth
Cara Therapeutics Inc. rank is 357 |
Target Prices
The average analysts' target price is $27.33 for Cara Therapeutics Inc. using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Cara Therapeutics Inc. is ranked 405. |
| Negative Rankings |
Price-to-Sales
Cara Therapeutics Inc. rank is 65 |
Negative Stoch Cross
Cara Therapeutics Inc. rank is 72 |
Negative Net Margin
Cara Therapeutics Inc. rank is 118 |
Down EPS Surprise
Cara Therapeutics Inc. missed the consensus earnings estimate when it last reported quarterly earnings. |
Negative ROA
Cara Therapeutics Inc. rank is 452 |
Negative ROE
Cara Therapeutics Inc. rank is 490 |
Price-to-Book
Cara Therapeutics Inc. rank is 562 |
Negative Revenue Growth
Cara Therapeutics Inc. rank is 703 |
